Form 4: Cytokinetics Director Lynne Parshall Reports Stock Transactions
SEC Form 4
Director Lynne Parshall reports exercising stock options and selling shares of Cytokinetics on July 15, 2024.
Summary
- On July 15, 2024, Lynne Parshall, a director of Cytokinetics Inc., executed transactions involving the company's common stock.
- Parshall exercised non-qualified stock options to acquire 5,000 shares at a price of $10.68 per share.
- Simultaneously, Parshall sold 5,000 shares at a price of $55.82 per share.
- Following these transactions, Parshall directly owns 20,600 shares of Cytokinetics Inc.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of stock transactions by a company director. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, providing transparency to the market regarding the buying and selling activities of company directors. It's common for directors to exercise stock options and sell a portion of the acquired shares for personal financial management.
Key Dates
| Date | Description |
|---|---|
| 06/17/2019 | Date the Non-Qualified Stock Option became exercisable |
| 05/14/2029 | Expiration date of the Non-Qualified Stock Option |
| 07/15/2024 | Date of stock option exercise and stock sale |
| 07/16/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.